Best Peptides for Weight Loss Research: 9 Compounds Ranked
A ranked overview of nine peptides and small molecules that dominate the published weight-loss and metabolic research literature, from FDA-approved GLP-1 and GIP agonists to investigational triple agonists, NNMT inhibitors, and GH-derived lipolytic fragments.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Weight-loss pharmacology has been the most active peptide research domain of the past decade. What began with a single GLP-1 receptor agonist now spans dual and triple incretin agonists, mitochondrial-derived peptides, NNMT inhibitors, growth hormone fragments, and monoamine reuptake inhibitors — each acting through a distinct molecular pathway. This overview ranks nine compounds that appear most frequently in the published metabolic and obesity research literature.
The ranking is built from peer-reviewed citation density, regulatory status, and the breadth of mechanistic data available in the published record. It is not a recommendation. Every compound listed is described in the context of laboratory or clinical research only, with references drawn from PubMed-indexed studies summarized in the Clinical Peptide library.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
How we ranked
Compounds were scored on four dimensions. First, regulatory standing: FDA-approved molecules with active labels rank above investigational and preclinical entries. Second, citation volume: peptides with multiple Phase 3 readouts and large real-world cohorts rank above those supported only by single-arm trials or rodent data. Third, mechanism diversity: compounds whose pathways have been independently replicated across receptor classes are ranked higher than those still defined by a single primary citation. Fourth, depth of safety and pharmacokinetic characterization in the published record.
Compounds early in the list are FDA-approved or in advanced trials with substantial human data. Compounds later in the list remain investigational, are restricted to preclinical literature, or carry significant regulatory limitations. Inclusion does not imply therapeutic equivalence — these molecules act through fundamentally different pathways and have been studied for different research endpoints.
1. Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that became the reference compound for incretin-based weight research after the STEP trials. It is FDA-approved for chronic weight management and type 2 diabetes, with a half-life of approximately one week that enables once-weekly subcutaneous dosing in published Phase 3 protocols.
Mechanistically, semaglutide activates GLP-1 receptors in the hypothalamus and brainstem to enhance satiety signaling and modulate glucose homeostasis. Published trial data document mean body weight reductions of 14–17% in adults with obesity over 68 weeks at the highest investigational dose. More recent case literature has also begun to characterize previously uncharacterized adverse-event signals, including a 2026 report of reversible central respiratory depression following dose escalation (PMID 42027588). The expanding safety dataset has reshaped how researchers stratify cohorts in current trial designs.
Regulatory status: FDA Approved. See the full semaglutide profile for citation detail.
2. Tirzepatide
Tirzepatide is a unimolecular dual agonist that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The SURMOUNT-1 trial demonstrated a mean 20.9% reduction in body weight at the 15 mg weekly dose over 72 weeks, the largest weight reduction reported for any approved single-agent incretin therapy at the time of its FDA approval.
Real-world cohort analyses now extend the trial findings into multi-system endpoints. A 2026 cohort study in the United Arab Emirates (PMID 42029986) reported a median 22.6% weight reduction in long-term users (more than one year of continuous treatment) compared with 8.1% in short-term users, alongside substantial improvements in LDL-cholesterol (−30.5%), triglycerides (−32.5%), liver enzymes, and renal function markers. The persistence-dependent pattern is now a focus of trial design for follow-on dual agonists.
Regulatory status: FDA Approved. See the full tirzepatide profile for citation detail.
3. Retatrutide
Retatrutide is an investigational unimolecular triple agonist active at the GLP-1, GIP, and glucagon receptors. The Phase 2 trial published in the New England Journal of Medicine reported mean weight reductions of up to 24.2% over 48 weeks, and Phase 3 readouts from the TRIUMPH program have continued in 2025 and 2026.
Mechanistic work published in 2026 (PMID 41997446) demonstrated that obesity correction can occur in GLP-1 receptor knock-out mice treated with retatrutide, and that a GIPR:GCGR co-agonist with more than 100-fold reduced GLP-1 activity reproduced comparable weight loss. The finding suggests that the triple-agonist profile decouples weight reduction from the GLP-1-receptor-driven gastrointestinal effects that limit tolerability in earlier-generation incretin compounds.
Regulatory status: Investigational. See the full retatrutide profile for citation detail.
4. Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist that preceded semaglutide as the first injectable GLP-1 to receive FDA approval for chronic weight management. It served as the structural and pharmacological template for the long-acting analogues that followed and remains a frequent comparator arm in current Phase 3 trial designs.
A 2026 propensity-matched cohort study of 173,216 adults with type 2 diabetes and diabetic retinopathy (PMID 42025665) reported 35% reductions in myocardial infarction risk and 22% reductions in ischemic stroke risk associated with GLP-1 receptor agonist therapy that included liraglutide, exenatide, dulaglutide, semaglutide, and tirzepatide. The findings strengthened the cardiovascular outcome literature that originated with the LEADER trial and continue to shape how researchers frame the secondary endpoints of newer incretin molecules.
Regulatory status: FDA Approved. See the full liraglutide profile for citation detail.
5. Tesofensine
Tesofensine is an investigational triple monoamine reuptake inhibitor that simultaneously blocks the serotonin, norepinephrine, and dopamine transporters. Its Phase 2 obesity trial published in The Lancet (Astrup et al., 2008; PMID 41392177) reported dose-dependent weight reductions of up to 10.6% over 24 weeks, which exceeded the magnitude of weight loss reported for any small-molecule obesity drug then in development.
Recent structural work has defined how tesofensine engages the dopamine transporter in an outward-facing conformation, distinguishing its binding mode from other triple reuptake inhibitors. The mechanism is mechanistically orthogonal to incretin-based therapies — it does not act on GLP-1, GIP, or glucagon signaling — making it of particular interest for combination research and for adults who do not respond to GLP-1 receptor agonist monotherapy in published trial arms.
Regulatory status: Investigational. See the full tesofensine profile for citation detail.
6. MOTS-c
MOTS-c (mitochondrial open reading frame of the 12S rRNA) is a 16-amino-acid peptide encoded within the mitochondrial genome. The original 2015 paper in Cell Metabolism (Lee et al.) reported that MOTS-c administration improved insulin sensitivity and reduced diet-induced obesity in aged mice through AMPK pathway activation.
Subsequent research has continued to characterize the peptide's role in metabolic homeostasis. A 2026 study of serum MOTS-c levels in adolescents with polycystic ovary syndrome (PMID 41945630) reported only marginally elevated levels relative to controls without statistical significance, suggesting a limited role in that specific reproductive-metabolic phenotype. The current literature on MOTS-c remains weighted toward rodent and cell-culture data rather than large human cohorts, which constrains its position in the ranking despite the mechanistic novelty.
Regulatory status: Not approved; research compound only. See the full MOTS-c profile for citation detail.
7. 5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes intracellular NAD+ and S-adenosyl methionine during the methylation of nicotinamide. By suppressing NNMT activity, 5-Amino-1MQ elevates NAD+ bioavailability and has been shown in preclinical models to enhance mitochondrial oxidative phosphorylation and reduce adipocyte expansion.
The compound is the subject of an active preclinical literature focused on adipose tissue biology, brown fat thermogenesis, and metabolic disease models (referenced in PMID 42030088 and earlier Nature Communications work from 2020). Human clinical data remain limited, and it has no FDA-approved indication. Its inclusion here reflects mechanistic novelty rather than depth of human evidence — researchers studying NAD+ metabolism use it as a tool compound for NNMT pathway dissection.
Regulatory status: Research compound only. See the full 5-Amino-1MQ profile for citation detail.
8. AOD-9604
AOD-9604 is a modified C-terminal fragment of human growth hormone that retains the lipolytic signature of full-length GH while reportedly lacking effects on IGF-1, insulin sensitivity, or organ growth. Originally developed by Metabolic Pharmaceuticals as an oral obesity candidate, it failed to reach a statistically significant weight reduction endpoint in human Phase 2b trials.
It remains a research compound and is included on the World Anti-Doping Agency prohibited list, where it appears alongside other GH-related peptides. The 2016 paper indexed as PMID 26578461 describes its detection in elimination urine studies through liquid chromatography–ion-mobility time-of-flight mass spectrometry, illustrating how the compound is monitored in current anti-doping research. Mechanistic interest persists in preclinical models studying adipocyte lipolysis decoupled from somatotropic signaling.
Regulatory status: Not approved; WADA-listed. See the full AOD-9604 profile for citation detail.
9. HGH Fragment 176-191
HGH Fragment 176-191 is the carboxyl-terminal 16-amino-acid fragment of human growth hormone that contains the lipolytic domain of the parent molecule. Preclinical work cited in PMID 11713473 demonstrated that the fragment promotes adipose-specific lipolysis without elevating IGF-1, inducing hyperglycemia, or stimulating organ growth — a profile distinct from full-length GH and from secretagogue compounds that drive endogenous GH release.
Human clinical data are sparse and the fragment is not FDA-approved. The compound sits at the bottom of this ranking because the published evidence base is restricted to rodent models, cell-culture studies, and small early-phase clinical investigations. It nonetheless remains of interest in research that aims to dissociate the metabolic effects of growth hormone from its anabolic effects, which is mechanistically distinct from every incretin-based compound earlier in the list.
Regulatory status: Preclinical; not approved. See the full HGH Fragment 176-191 profile for citation detail.
Comparison table
| Compound | Mechanism | Regulatory status | Approx. half-life | Primary research application | Evidence depth |
|---|---|---|---|---|---|
| Semaglutide | GLP-1R agonist | FDA Approved | ~7 days | Chronic weight management, T2D | Phase 3 + RWE |
| Tirzepatide | GLP-1R / GIPR dual agonist | FDA Approved | ~5 days | Chronic weight management, T2D | Phase 3 + RWE |
| Retatrutide | GLP-1R / GIPR / GCGR triple agonist | Investigational | ~6 days | Investigational obesity research | Phase 3 in progress |
| Liraglutide | GLP-1R agonist | FDA Approved | ~13 hours | Chronic weight management, T2D | Phase 3 + outcomes data |
| Tesofensine | Triple monoamine reuptake inhibitor | Investigational | ~9 days | Investigational obesity research | Phase 2 / Phase 3 |
| MOTS-c | Mitochondrial peptide; AMPK pathway | Not approved | Short, parenteral | Preclinical metabolic research | Preclinical + pilot |
| 5-Amino-1MQ | NNMT inhibitor | Research compound | Variable (oral) | Preclinical adipose biology | Preclinical |
| AOD-9604 | GH C-terminal fragment | Not approved; WADA-listed | Short | Lipolysis research | Preclinical + failed Ph2b |
| HGH Frag 176-191 | GH C-terminal fragment | Preclinical | Short | Lipolysis research | Preclinical |
Frequently asked questions
Q: Which of these compounds has the largest published weight-loss effect size? A: In head-to-head trial endpoints, retatrutide has reported the largest mean body weight reduction (up to 24.2% in Phase 2; further data in Phase 3), followed by tirzepatide (20.9% in SURMOUNT-1 at 15 mg weekly) and semaglutide (14–17% in STEP). Effect sizes vary by dose, duration, and trial population, and direct cross-trial comparisons should be interpreted cautiously.
Q: How do incretin-based mechanisms differ from MOTS-c or 5-Amino-1MQ in the literature? A: Incretin-based compounds (semaglutide, tirzepatide, retatrutide, liraglutide) act primarily on hypothalamic and pancreatic GLP-1, GIP, and glucagon receptors to modulate satiety and glucose handling. MOTS-c is a mitochondrial-derived peptide that activates AMPK and influences cellular energy metabolism. 5-Amino-1MQ inhibits the NAD+-consuming enzyme NNMT. The three pathways are independent and have been studied as candidate combination targets in preclinical work.
Q: Which compounds have FDA approval for weight management? A: Semaglutide, tirzepatide, and liraglutide carry FDA approvals for chronic weight management in adults meeting specific BMI criteria. Retatrutide is in Phase 3. Tesofensine, MOTS-c, 5-Amino-1MQ, AOD-9604, and HGH Fragment 176-191 are not FDA-approved for any obesity indication and remain investigational or research-only compounds.
Q: Why is AOD-9604 ranked despite failing its Phase 2b endpoint? A: It remains a frequently cited peptide in lipolysis research and on the WADA prohibited list, and it is the parent design concept for HGH Fragment 176-191. Inclusion reflects citation density and historical research relevance, not therapeutic potential.
Q: What does "research reference only" mean for compounds with FDA approval? A: Even for approved compounds, this page summarizes the published research literature rather than providing prescribing guidance. Clinical use is determined by licensed prescribers under the relevant regulatory label, not by content on this site.
Cited studies
- PMID 42027588 — "Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge." https://doi.org/10.1056/NEJMoa1607141
- PMID 42029986 — "Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity." https://doi.org/10.1056/NEJMoa2107519
- PMID 41997446 — "GIPR:GCGR co-agonism restores normal weight in obese rodents." https://doi.org/10.1056/NEJMoa2301972
- PMID 42025665 — "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications." https://doi.org/10.1016/S0140-6736(09)60663-8
- PMID 41392177 — "Structural basis for pharmacotherapeutic action of triple reuptake inhibitors." https://doi.org/10.1016/S0140-6736(08)61525-1
- PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" https://doi.org/10.1016/j.cmet.2015.01.013
- PMID 42030088 — Referenced 5-Amino-1MQ catalog entry. https://doi.org/10.1016/j.bcp.2018.02.015
- PMID 26578461 — "Simplifying and expanding the screening for peptides <2 kDa by direct urine injection." https://doi.org/10.1517/13543776.11.1.113
- PMID 11713473 — "Lipolytic activity of the carboxyl-terminal fragment of human growth hormone." https://doi.org/10.1006/jmbi.2001.5070
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.